Skip to Main Content

Mechanistic Evaluation of Guanfacine on Drinking Behavior

Conditions

Mental Health & Behavioral Research

Phase COVID-II

What is the purpose of this trial?

In this study, we are seeking individuals who are interested in reducing or cutting back their drinking behavior. We will be looking at how the medication Intuniv, which is Guanfacine, influences drinking behavior. Guanfacine is a medication that has been approved by the Food and Drug Administration (FDA) to treat high blood pressure and ADHD. There are three phases to the study.

  • Trial with
    National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  • Start Date
    03/01/2019
  • End Date
    09/29/2026

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/15/2021
  • Study HIC
    #2000023970